Skip to search formSkip to main contentSkip to account menu

fingolimod

Known as: Fingolimodum 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BackgroundThe likelihood to help or harm (LHH) is an absolute measure of the benefit versus risk profile of a medication, which… 
Review
2016
Review
2016
Cite this article: Clark SJ, Wang Q, Mao-Draayer Y (2016) Switching from Natalizumab to Fingolimod: Case Report and Review of… 
Review
2016
Review
2016
Purpose of Review:This article provides an evidence-based approach to the management of patients with early relapsing multiple… 
2015
2015
Diabetes mellitus (DM) affects the function of blood vessels and various organs, eventually leading to life-threatening DM… 
2015
2015
OBJECTIVE: PANGAEA (Post-Authorization Non-interventional German sAfety study of GilEnyA in RRMS patients) is a non… 
Review
2014
Review
2014
Neuro-Ophthalmic Literature Review Carmen K. M. Chan, Axel Petzold, Evan Price, John H. Pula, Matthieu Robert, Michael Vaphiades… 
Review
2013
Review
2013
ABSTRACT Multiple sclerosis (MS) is a complex disease that affects the central nervous system. It is believed to be an immune… 
2012
2012
Multiple sclerosis (MS) therapies modulate T-cell autoimmunity in the central nervous system (CNS) but may exacerbate latent… 
2011
2011
Fingolimod was synthesized from 1-phenyloctane and 3-bromopropionylchloride by Friedel-Crafts acylation,nitration,reduction… 
2008
2008
mune-modulating drug, fingolimod (FTY 720) seems promising as a treatment for relapsing-remitting multiple sclerosis (RRMS…